Replies to post #128595 on Biotech Values

[mcbio]

I still don’t get it. Unless there was a bidding war for ANDS, which seems unlikely, why would Roche move on ANDS now if the ultimate plan were to acquire ACHN later?

Well, ANDS did have a relatively tiny valuation so perhaps Roche thought it best to go ahead and acquire ANDS at this level. And ANDS and ACHN aren't mutually exclusive acquisitions since it could conceivably make sense to pair an ANDS non-nuke with an ACHN PI and/or NS5A inhibitor.

[dav1234]

Shares of Anadys (ANDS) Trade Above $1; Analyst Believes Co. Could Get a Bid Following Setrobuvir Data
Oct 6, 2011
William Blair's Katherine Xu believes Anadys Pharma (Nasdaq: ANDS) may be acquired following the release of top-line 12-week Setrobuvir Phase IIb data sometime next week (or by mid-October at the latest). The analyst attaches a 50 percent chance of a buyout.

Xu notes Johnson & Johnson (NYSE: JNJ), Boehringer Ingelheim, GaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) are all possible suitors for the acquisition.

William Blair has an Outperform rating and $4 price target on shares of Anadys.

Shares of ANDS are trading up 7.1 percent to just barely over $1. Notably, the stock has not traded over this level since the beginning of August.


pretty good call by this analyst,lol

http://www.streetinsider.com/Analyst+Comments/Shares+of+Anadys+%28ANDS%29+Trade+Above+%241%3B+Analyst+Believes+Co.+Could+Get+a+Bid+Following+Setrobuvir+Data/6839646.html